Daré Bioscience (DARE) AI Stock Analysis

• Market Cap: $26.37M
• Dividend Yield: N/A
• Average Volume (3M): 16.20K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.32
• Revenue Growth: 88.13%
• EPS Growth: 92.45%
• Country: US
• Employees: 21
• Sector: Healthcare
• Sector Strength: 56
• Industry: Biotechnology
• EPS (TTM): -0.44
• Shares Outstanding: 8,850,386
• 10 Day Avg. Volume: 9,993
• 30 Day Avg. Volume: 16,200
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.85
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 8.06
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $12.00
• Price Target Upside: 302.68% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

Daré Bioscience's stock score reflects significant financial instability, with high liabilities and negative equity being major concerns. While there are strategic initiatives and some technical support, these are offset by financial distress and speculative valuation, resulting in an overall cautious outlook.

Positive Factors

Funding and Financial Resources

Daré's cash position is expected to be sufficient to fund operations into late 2025, aided by the $5.7M upfront from the Gates foundation.

Regulatory Advancements

The FDA's agreement on just a 12-week treatment period for the sildenafil cream Phase 3 trial is significant, potentially accelerating the study timeline.

Strategic Partnerships

The company expanded its pipeline through a new partnership with Theramex to develop Casea S, a long-acting contraceptive implant.

Negative Factors

Financial Risks

Risks include financial because the company has capital needs greater than the current cash balance, likely necessitating additional capital raises.

Regulatory Challenges

Sildenafil cream is intriguing but still needs FDA alignment, and there is uncertainty around the regulatory pathway.

Daré Bioscience Business Overview & Revenue Model

Company Description

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar and vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ADARE-204 and ADARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. Daré Bioscience, Inc. is headquartered in San Diego, California.

How the Company Makes Money

Daré Bioscience makes money primarily through strategic partnerships, licensing agreements, and potential future revenues from product sales pending regulatory approval and commercialization. The company enters into collaborations with larger pharmaceutical companies for the development and commercialization of its product candidates, which can provide revenue in the form of milestone payments and royalties on sales. Additionally, Daré may receive funding and grants from government bodies or non-profit organizations focused on advancing women's health. Given that Daré is still in the clinical-stage, it relies heavily on investment capital and partnerships to finance its operations and support the advancement of its product pipeline.

Daré Bioscience Financial Statement Overview

Summary

Daré Bioscience faces significant financial challenges, with persistent unprofitability, negative equity, and high liabilities indicating financial distress. Despite recent positive trends in cash flow and revenue growth, the company's long-term sustainability remains questionable without a turnaround in profitability and a more stable balance sheet.

Income Statement

Daré Bioscience has struggled with profitability, as evidenced by consistently negative net income over the years. While there was a notable increase in revenue in 2024, the gross profit margin remains 100% due to revenue equaling gross profit, but this is overshadowed by significant negative EBIT and EBITDA margins, indicating high operational costs. The revenue growth from 2023 to 2024 is positive, which is a good sign, but the company remains unprofitable overall.

Balance Sheet

The balance sheet reveals a worrying situation with negative stockholders' equity, indicating financial instability. Additionally, the debt-to-equity ratio is not applicable due to negative equity, and the company is highly leveraged with total liabilities exceeding total assets. The negative equity ratio suggests insolvency risk, which is a significant concern for stakeholders.

Cash Flow

While Daré Bioscience has managed to generate a positive operating cash flow in 2024, indicating some operational efficiency, the free cash flow remains inconsistent over the years. The positive free cash flow to net income ratio in 2024 is a positive indicator, but the historical volatility in cash flows points to potential financial management challenges.

Breakdown
Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
2.81M	10.00M	0.00	0.00	0.00
	Gross Profit
2.77M	9.95M	-26.41K	-43.23K	-11.14K
	EBIT
-30.84M	-31.39M	-39.07M	-27.40M	-14.34M
	EBITDA
-30.90M	-31.36M	-39.04M	-27.36M	-14.33M
	Net Income Common Stockholders
-30.16M	-30.95M	-38.33M	-27.40M	-14.26M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
10.48M	34.67M	51.67M	4.67M	4.78M
	Total Assets
21.28M	43.83M	55.81M	7.55M	7.44M
	Total Debt
1.40M	488.74K	270.55K	756.84K	800.45K
	Net Debt
-9.07M	-34.18M	-51.40M	-3.91M	-3.98M
	Total Liabilities
26.33M	32.71M	17.05M	8.70M	7.00M
	Stockholders Equity
-5.05M	11.11M	38.75M	-1.15M	440.83K
Cash Flow		Free Cash Flow
-39.49M	-18.15M	-28.78M	-25.25M	-13.32M
	Operating Cash Flow
-38.86M	-18.09M	-28.76M	-25.23M	-13.32M
	Investing Cash Flow
-629.43K	-63.07K	-14.52K	-17.63K	6.14M
	Financing Cash Flow
15.64M	1.34M	75.85M	25.13M	5.15M

Daré Bioscience Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.98
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DARE, the sentiment is Positive. The current price of 2.98 is above the 20-day moving average (MA) of 2.94, above the 50-day MA of 2.96, and below the 200-day MA of 3.29, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 53.99 is Neutral, neither overbought nor oversold. The STOCH value of 37.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DARE.

Daré Bioscience Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.35B	3.81	-42.57%	2.86%	17.10%	1.33%
DARE	46 Neutral	$26.37M	―	597.53%	―	88.13%	92.45%
VYNE	43 Neutral	$20.84M	―	-56.54%	―	18.16%	86.65%
PYPD	41 Neutral	$28.43M	―	-1038.73%	―	―	34.97%
CLNN	39 Underperform	$26.52M	―	-1738.36%	―	-47.71%	-244.00%
GBIO	38 Underperform	$29.21M	―	-91.02%	―	236.92%	-0.57%
NRSN	30 Underperform	$24.71M	―	-2880.11%	―	―	31.09%

Daré Bioscience Corporate Events

Daré Bioscience to Present at BIO CEO Conference

Daré Bioscience plans to present a corporate presentation at the BIO CEO & Investor Conference in New York on February 10, 2025, and use it in various meetings with market participants. The presentation will be available on their website, indicating a strategic move to engage with investors and stakeholders.